Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating MCLA-158, a bispecific antibody targeting EGFR and LGR5, in patients with advanced or metastatic solid tumors, including metastatic colorectal cancer mCRC and head and neck squamous cell carcinoma HNSCC. This Phase 12 open-label, multi-center study aims to find the recommended dose for further testing and assess the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and anti-tumor activity of MCLA-158 alone or combined with other treatments. The study has two parts an initial dose escalation phase that determined the recommended Phase II dose RP2D of MCLA-158, and an expansion phase where this dose is given every two weeks by intravenous infusion to patients with selected solid tumors. The expansion includes single-agent cohorts and combination cohorts where MCLA-158 is tested with pembrolizumab, FOLFIRI chemotherapy, or FOLFOX chemotherapy. Different doses and a subcutaneous formulation are also evaluated in some groups. Participants receive treatment cycles lasting 28 days with infusions on Day 1 and Day 15. Researchers monitor safety through adverse events and dose-limiting toxicities, tumor response, drug levels in blood, and other clinical and laboratory assessments over months to years. The study includes regular evaluations with imaging, laboratory tests, and heart function monitoring, with follow-up extending up to three years to assess response duration, progression-free survival, and overall survival.